处于临床研究阶段的抗结核新药研究进展  

Advance in the research of new anti-tuberculosis drugs in clinical trials

作　　者：赵冬梅[1] 张学辉[2] 钟武[2] 李松[2] 

机构地区：[1]沈阳药科大学制药工程学院,沈阳110016 [2]军事医学科学院毒物药物研究所,北京100850

出　　处：《中国新药杂志》2009年第12期1091-1094,共4页Chinese Journal of New Drugs

基　　金：国家重点基础研究发展计划(973计划)资助项目(No.2004CB518908)

摘　　要：结核病的再度爆发和耐药结核分枝杆菌的出现,使结核病再次成为威胁人类健康的主要疾病之一。而在过去的40年里未开发出新型高效的抗结核药物。研究抗结核药物来有效地预防和治疗结核感染是非常必要的。目前世界范围内已经进入临床阶段的抗结核新药有莫西沙星、加替沙星、利福喷汀、利福拉齐及TMC207,PA-824,OPC-67683,SQ-109,LL3858等。文中分别介绍了这些新药的化学结构、作用机制、抗结核活性以及临床应用进展。The resurgence of tuberculosis （TB） and the surge of multidrug-resistant of Mycobacterium have reaffirmed tuberculosis as a primary public healthy concern. However, it has been nearly 40 years since the introduction of a new class of effective compounds for the treatment of TB. Therefore, there is an urgent need to develop new antituberculosis drugs. At present, the new drugs that have been in the stage of clinical trial include moxifloxacin, gatifloxacin, rifapentine, rifalazil, TMC207, PA-824, OPC-67683, SQ-109 and LL3858. This article summarized their structures, mechanism, activity and clinical application.

关 键 词：抗结核新药 耐药结核分枝杆菌 临床研究 

分 类 号：R978.3[医药卫生—药品]